All "premalignant" lesions need to be characterized with regard to DNA sequence, RNAseq, proteomics, lipidomics, miRNA ect to fully understand a basis for preventing the progression of these early disease states
"Field-effect" and its importance in cancer has been proposed in the 50's. Hypermethylation can silence some tumor suppressor genes while cause some genes to overexpress.
Could you all do research on use of vitamin C to kill cancer cells?? I heard that UT Southwestern was doing something like that.
Metastasis causes 90% of cancer deaths, but we atull know very little about the metastatic process and how to stop it. Research in this area is vital to saving lives.
Cancer arising from lobules of the breast vs ducts accounts for 10% of all breast cx. Invasive lobular carcinoma is extremely hard to detect via palpating/imaging. Dense breast tissue makes it even harder to find. Yet little research is being done.
I feel funding advancements for "In-Cell" Imaging would be wise. For example, a lot information into tumorigenesis may be obtained if we were able to differentially image Histone acetylases/deacetylase activity within intact tissue.
Amassing blood biopsies of patients with cancer and finding genetic correlates of heme and tumor genomes to response would be useful.
A large scale study would yield important data, but must be paired with powerful tools of analysis.
CRISPS Case 9 and immunotherapy, separately, and, in combination therapy, could induce apoptosis, destroying cancer cells and tumors.
Limited data is available on the molecular and biochemical characteristics of common cancers in Nigeria compared to other blacks and races. The information obtained will help to understand tumor behavior and progression
Unfortunately, in most patients, it is a minority of drug-resistant tumor cells that are present but not detected at diagnosis (or that evolve) that kill patients. No 'omics technology is good enough at single cell analysis to solve this problem.
High grade gliomas are the deadliest brain tumors known. Despite a combination of surgery, radiation, and chemotherapy, most patients die within 2 years. We need to identify the stem cell minority and target them with advanced therapies.
The theory of dynamic cell attractors provides a theoretical framework for understanding how to reprogram ordinary cells into stem cells. Similarly, it can be used to engineer solutions to reprogramming cancer cells into non-proliferative states.
Mitochondria is central to cancer progression & several drugs don't act on cancer cells with bad quality mitochondria. It has been reported that Cancer cell phenotype can be reversed by replacing mitochondria.
Data and outcomes can be clouded by the fact that no one questions a diagnosis. Pathologists and oncologists can make mistakes. We need to prevent cancers from being treated inappropriately because no one thought reevaluate a diagnosis.
A clinical trial using *currently FDA approved drugs* (Everolimus and Temsirolimus) targeting PTEN mutation to control the evolution of metastatic ER+ breast cancer is Urgently needed. See attached article for the basis for this trail.